To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
Subjects must voluntarily participate in the study and sign the informed consent form.
Aged between 18 and 75 years (inclusive) at the time of signing the informed consent form.
Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.
Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;
Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.
Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.
Major surgical procedures, significant traumatic injuries, or unhealed wounds or fractures within 28 days prior to the first dose.
Any bleeding or hemorrhagic event of ≥ Grade 3 according to CTC AE criteria within 4 weeks prior to the first dose.